Quoin Pharmaceuticals (QNRX) Other Non-Current Liabilities (2017 - 2026)

Quoin Pharmaceuticals has reported Other Non-Current Liabilities for 9 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.3 million, down 20.52% from the prior year.
• Other Non-Current Liabilities eased to $2.2 million in Q1 2026 per QNRX's latest filing, from $2.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $9.9 million in Q3 2022 and troughed at $1.9 million in Q3 2025.
• A 5-year average of $3.3 million and a median of $2.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 1003.79% in 2022, then sank 62.93% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $4.1 million in 2022, then fell by 29.1% to $2.9 million in 2023, then changed by 0.0% to $2.9 million in 2024, then declined by 20.52% to $2.3 million in 2025, then slipped by 6.46% to $2.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.2 million, $2.3 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.